| Pair Name | Obovatol, Docetaxel | ||
| Phytochemical Name | Obovatol (PubChem CID: 100771 ) | ||
| Anticancer drug Name | Docetaxel (PubChem CID: 148124 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Obovatol, Docetaxel | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | NFKB1 | hsa4790 |
| In Vitro Model | LNCaP | Prostate carcinoma | Homo sapiens (Human) | CVCL_0395 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| SW620 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0547 | |
| HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 | |
| Result | These results indicate that obovatol augments cell growth inhibition by chemotherapeutics through inactivation of NF-kappaB and suggest that obovatol may have therapeutic advantages in the combination treatment with other chemotherapeutics. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J Pharmacol Sci. 2009 Oct;111(2):124-36. doi: 10.1254/jphs.09048fp. | Click |
